Ahead of the Bell: Analyst lowers Vertex target
Originally posted in Fibrosis News
Vertex Pharmaceuticals will face challenging competition for its hepatitis C drug Incivek, but the drugmaker also has a promising cystic fibrosis treatment, according to a report from Citi Investment Research & Analysis.
No Comments »
RSS feed for comments on this post. TrackBack URL
by Raelene
